A federal appeals court affirmed the validity of Sanofi's first patent on prostate-cancer drug, Jevtana, and also overturned a ruling against a later patent on a method of administering it.
Would-be generic competitors, including Fresenius, Mylan and Apotex lost bids to invalidate the patent covering Jevtana. The patent will expire in 2021.
Jevtana accounted for 1.5 percent of Sanofi's Q2 total sales and 29.2 percent of its oncology franchise sales.
Read the Bloomberg coverage
Don't miss your Daily Dose. Get news like this delivered right to your inbox.